drugset / Trial / NCT00192660
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
Phase 4
Completed
80 enrolled
Kirby Institute
National Heart, Lung, and Blood Institute (NHLBI) · collabSt Vincent's Hospital, Sydney · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is a prospective, non-randomised, 48 week study of the effect of protease inhibitor (PI) containing and non-PI containing antiretroviral regimens on the expression of adipocyte specific genes, protein levels and cellular structure in HIV-infected individuals, naive to therapy, who are starting therapy for the first time.
Timeline
- Start
- 2003-02
- Primary completion
- 2006-10
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abacavir | Other / unclassified | — | — |
| Subject | Amprenavir | Other / unclassified | — | — |
| Subject | Didanosine | Small molecule | — | — |
| Subject | Efavirenz | Other / unclassified | — | — |
| Subject | Enfuvirtide | Peptide | — | — |
| Subject | INDINAVIR ANHYDROUS | Other / unclassified | — | — |
| Subject | Lamivudine | Other / unclassified | — | — |
| Subject | Nelfinavir | Other / unclassified | — | — |
| Subject | Nevirapine | Small molecule | — | — |
| Subject | Ritonavir | Other / unclassified | — | — |
| Subject | Saquinavir | Small molecule | — | — |
| Subject | Stavudine | Other / unclassified | — | — |
| Subject | Tenofovir | Small molecule | — | — |
| Subject | Tipranavir | Small molecule | — | — |
| Subject | Zidovudine | Small molecule | — | — |